---
title: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
date: '2023-11-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37952131/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231113170821&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: In patients with preexisting cardiovascular disease and
  overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a
  dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular
  causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of
  39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, ...